Should you buy Telix Pharmaceuticals (TLX)?
Updated
Telix Pharmaceuticals is growing revenue 49% year-over-year with analyst consensus implying 86% upside to $17.77 and high asymmetry of 9.7, but the quality score of 2.6 is deeply below the investment floor and the company is cash-flow negative, making this a speculative recovery story.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus implies 86.3% upside from the current price of $9.54 to a target of $17.77, and the asymmetry ratio of 9.68 is among the highest in the quantitative model, reflecting strong analyst conviction that the stock is materially undervalued. Targets | Price rises above $14 within 12 months, closing more than 50% of the gap toward the analyst consensus target of $17.77. | →Stable |
| CounterHigh analyst upside with a PEG of 0.03 and forward price-to-earnings of 40.4x suggests that the target reflects a large expected earnings ramp that has not yet materialized, making the upside contingent on significant execution. | ||
Revenue grew 49% year-over-year, earning a maximum growth score of 10.0 out of 10, demonstrating that Telix is rapidly scaling its radiopharmaceutical business from a small base. Growth breakdown | Year-over-year revenue growth remains above 25% for at least 3 of the next 4 reported periods. | →Stable |
| CounterHigh revenue growth in early-stage biotech companies frequently decelerates sharply as initial market penetration is achieved, and 49% growth from a small base may not be indicative of the sustainable trajectory. | ||
The quality score of 2.6 is severely below the minimum floor of 4.0, and the company is cash-flow negative with a free cash flow burn rate of -5% of revenue, indicating the business model has not yet reached operational self-sufficiency. Warnings | Quality score rises above 4.0 and free cash flow turns positive on a trailing twelve-month basis within the next 12 months. | →Stable |
| CounterMany successful biotechs and radiopharmaceutical companies invest heavily in commercial infrastructure during the early scaling phase, and cash burn at -5% of revenue is relatively modest compared to development-stage peers. | ||
Analyst consensus implies 86.3% upside from the current price of $9.54 to a target of $17.77, and the asymmetry ratio of 9.68 is among the highest in the quantitative model, reflecting strong analyst conviction that the stock is materially undervalued.
→Stable- Expectation
- Price rises above $14 within 12 months, closing more than 50% of the gap toward the analyst consensus target of $17.77.
CounterHigh analyst upside with a PEG of 0.03 and forward price-to-earnings of 40.4x suggests that the target reflects a large expected earnings ramp that has not yet materialized, making the upside contingent on significant execution.
Revenue grew 49% year-over-year, earning a maximum growth score of 10.0 out of 10, demonstrating that Telix is rapidly scaling its radiopharmaceutical business from a small base.
→Stable- Expectation
- Year-over-year revenue growth remains above 25% for at least 3 of the next 4 reported periods.
CounterHigh revenue growth in early-stage biotech companies frequently decelerates sharply as initial market penetration is achieved, and 49% growth from a small base may not be indicative of the sustainable trajectory.
The quality score of 2.6 is severely below the minimum floor of 4.0, and the company is cash-flow negative with a free cash flow burn rate of -5% of revenue, indicating the business model has not yet reached operational self-sufficiency.
→Stable- Expectation
- Quality score rises above 4.0 and free cash flow turns positive on a trailing twelve-month basis within the next 12 months.
CounterMany successful biotechs and radiopharmaceutical companies invest heavily in commercial infrastructure during the early scaling phase, and cash burn at -5% of revenue is relatively modest compared to development-stage peers.
▸ Show 1 more pillar▾ Show fewer
Rising on-balance volume near the 52-week low, with the stock only 0.3% above its annual trough, suggests buyers are accumulating at distressed prices — a pattern that historically precedes a recovery when growth fundamentals are improving.
→Stable- Expectation
- On-balance volume rises for more than 60 consecutive days and price climbs above $12, more than 25% above the current $9.54.
CounterWith the stock at the 52-week low and short interest at 10%, on-balance volume accumulation may be offset by continued short-selling pressure that caps any recovery attempt.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst consensus implies 86.3% upside from the current price of $9.54 to a target of $17.77, and the asymmetry ratio of 9.68 is among the highest in the quantitative model, reflecting strong analyst conviction that the stock is materially undervalued.
Trip ifAnalyst consensus price target falls below $12, more than 30% below the current target of $17.77, signaling a meaningful downward revision to the upside case.
- P2Revenue grew 49% year-over-year, earning a maximum growth score of 10.0 out of 10, demonstrating that Telix is rapidly scaling its radiopharmaceutical business from a small base.
Trip ifYear-over-year revenue growth falls below 15% in at least 2 of the next 4 reported periods, signaling significant deceleration from the 49% current pace.
- P3The quality score of 2.6 is severely below the minimum floor of 4.0, and the company is cash-flow negative with a free cash flow burn rate of -5% of revenue, indicating the business model has not yet reached operational self-sufficiency.
Trip ifFree cash flow burn rate increases to greater than -15% of revenue, more than tripling the current -5% rate and signaling accelerating capital consumption.
- P4Rising on-balance volume near the 52-week low, with the stock only 0.3% above its annual trough, suggests buyers are accumulating at distressed prices — a pattern that historically precedes a recovery when growth fundamentals are improving.
Trip ifPrice drops below $8, more than 16% below the current $9.54, confirming the 52-week low has been breached and the accumulation thesis has failed.
How the engine reached this verdict
TrendMatrix's engine output for Telix Pharmaceuticals Limited (TLX) is SELL_IF_HOLDING with medium conviction, score 6.1/10 at $10.90. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $10.90, with structural invalidation at $10.24. The asymmetric R:R against a reversal hypothesis is 9.70 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Quality below floor (2.6 < 4.0). Active engine warnings: Quality below floor (2.6 < 4.0).
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates TLX — 10-dimension breakdown →
Bear case
- ▸Quality below floor (2.6 < 4.0)